key: cord-0791884-456pp1ng authors: Castaneda-Sabogal, A.; Chambergo-Michilot, D.; Toro-Huamanchumo, C. J.; Silva-Rengifo, C.; Gonzales-Zamora, J.; Barboza, J. J. title: Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis date: 2021-01-27 journal: nan DOI: 10.1101/2021.01.26.21250420 sha: 345a045cbef06a341a87efdd0d36fb1830c0c5d7 doc_id: 791884 cord_uid: 456pp1ng Background: To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19. Methods: Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatorys or hospitalized participants. The primary outcome was overall mortality. Secondary outcome was the recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE. Results. After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin is not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I2= 84.7%), and it was not associated with reduced patient recovery (logRR 5.52 , 95% CI -24.36 to 35.4, p = 0.51, I2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence. Conclusions: There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19. Since the first reported case of severe respiratory syndrome coronavirus 2 (SARS-CoV-2), in December 2019 in Wuhan, China; cases of coronavirus disease (COVID- 19) have increased exponentially, with more than 95 million infected people worldwide until January 18, 2021 (https://coronavirus.jhu.edu/map.html). This high volume of COVID-19 cases has led to several problems including an overburdened health system, and a worrisome shortage of healthcare personnel. In this setting, finding an effective therapy against SARS-CoV-2 has become an urgent need (1) The current treatment of COVID-19 has been limited to general supportive care, because studies evaluating the efficacy of treatment in patients with COVID-19 have had several limitations and no treatment has demonstrated strong evidence for widespread recommendation (2) . Ivermectin is a semisynthetic anthelmintic agent that selectively binds to glutamate-gated chloride ion channels found in nerve and muscle cells of invertebrates (3) . However, an antiviral activity in RNA and DNA viruses has also been reported (4). increments); 120 mg MD and 60 mg three times weekly (every 72 hours) and concluded that the inhibitory concentration (IC 50 ) of ivermectin was not expected to inhibit SARS-CoV-2 in lung tissue even simulating with 10 times the approved dose in humans. Similar findings were reported by Caly et al (5, 6) . We conducted a systematic review and meta-analyses to evaluate the clinical efficacy of ivermectin for the treatment of COVID-19. This will provide clinicians with an overview of the scientific evidence on a potential treatment option, which will help in the clinical management of COVID-19 patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.26.21250420 doi: medRxiv preprint This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (7) . We searched PubMed, Scopus, Web of Science, Ovid-Medline, Embase, websites for preprints/preproofs ("Other sources"; https://www.medrxiv.org, https://preprints.scielo.org/index.php/scielo, https://www.biorxiv.org, https://arxiv.org), websites for protocols of clinical trials (https://clinicaltrials.gov). We performed a search strategy for each database. The complete search strategy is found in Supplementary file. We included all the original published studies (either as preprints or in scientific journals) of clinical trials, non-randomized studies of intervention, and retrospective cohorts, without language restrictions, from inception to January 21, 2020; that have included patients (ambulatory or hospitalized) with COVID-19, and have compared a group that received ivermectin with a group that did not; regardless of their study design. Systematic reviews, narrative reviews, conference proceedings, editorials, and letters to the editor without original data were excluded. Primary outcome was overall mortality. Secondary outcome was recovered patients. Two authors (JJB, DCM) independently screened search results by title and abstract according to the inclusion and exclusion criteria, using a web program Rayyan (rayyan-6 qcri.org). Also, two authors (JJB, DCM) independently assessed relevant studies and selected by full-text for the next phase of assessment. Discrepancies were consulted with another author (ACS), and a consensus was reached. The selection of articles in each stage of the review process was made using the Endnote X9 software. Two authors (JJB, DCM) independently extracted the data using pre-piloted Excel spreadsheets. Again, discrepancies were consulted with another author (ACS). The data extracted from each study were: Author, year, country, type of study, number of patients with ivermectin treatment, treatment/comparison or control arm, characteristics and condition of the patient when the treatment was received, methods of assessment and confounding variables, outcomes, and absolute effect of ivermectin versus control. Regarding the outcome of recovered patients, this variable was evaluated according to the criteria considered by the authors of each included study. Two investigators (JJB, DCM) independently assessed the risk of bias by using the ROBINS-I (Risk Of Bias In Non-Randomized Studies of Interventions) tool (8) for cohort studies and the Cochrane Risk of Bias 2.0 tool (9) for trials; disagreements were resolved by discussion with a third investigator (ACS). We assessed the certainty of evidence using the GRADE methodology (10) . When possible, we meta-analyzed results of RCTs and non-randomized studies that have used methods to control by possible confounders. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.26.21250420 doi: medRxiv preprint Random-effects models with Hartung-Knapp adjustment for random effects model, and the inverse variance method were used for all meta-analyses. Effects of ivermectin were described with log relative risks (LogRRs) with 95% confidence intervals (Log RR 95% CIs) for dichotomous outcomes in the observational studies that were assessed. Heterogeneity among studies was assessed using the I 2 statistic: 0-30% meant low, 30-60% moderate, and >60% high heterogeneity (11) . Subgroup analysis by year (<60 years vs >60 years), condition (outpatient vs inpatient), and need of oxygen support (with vs without oxygen support) was proposed; however, due to the insufficient published evidence, these aspects were not evaluated. A sensitivity analysis was performed excluding those studies without adjustment for confounding. (12) . This is a systematic review of published and open information, in which no human subjects participated. No ethics committee approval was required. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.26.21250420 doi: medRxiv preprint The search yielded 532 results. After duplicates were excluded, 232 titles and abstracts were reviewed, 210 of these were excluded, and 22 scientific papers were evaluated in detail. Finally, 12 studies were included in the qualitative synthesis (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , and five studies were included in the quantitative synthesis ( Figure 1 ). Most studies were pre-print studies and two studies (18, 22) were anticipated results of clinical trials protocols. Main characteristics of included studies are summarized in Table 1 . Two studies were located in USA (21, 22) , two from South America (15, 23) , one from Iraq (16) , two from Spain, one from Iran, and four from Bangladesh (13, 17, 18, 20) . Five retrospective cohort studies (14, 16, 17, 21, 23, 25) , six clinical trials (13, 18-20, 22, 24) , and one case series (15) were found. There were 7412 reported participants, the mean age was 47.5 (SD 9.1) years, and 4283 (58%) were male. The treatment was ivermectin (alone or with azithromycin, hydroxychloroquine, dexamethasone, enoxaparin, aspirin or dicloxacillin). Only one study reported no control group (15) . Most patients were hospitalized and confirmed COVID-19 by RT-PCR, except for individuals included in one study evaluating asymptomatic families (22). Regarding methods of assessment and confounding variables, two studies analyzed the confounding variables by propensity score weighting and adjusted by age, sex, location, type of admission, comorbidities, antibiotics applied and other drugs (21, 23). One study assessed these variables by logistic and Cox regression adjusted by age, sex, comorbidities and use of other drugs (21). One study assessed the variables by Kaplan Meier survival curve, adjusted by age, gender, and severity (16) . Finally, eight studies were not adjusted by confounding . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.26.21250420 doi: medRxiv preprint variables because they only applied bivariate analysis (13-15, 17-20, 22) . Different outcomes were evaluated by included studies, and most studies have assessed mortality and recovered patients as the primary outcome. Only four studies did not describe data regarding mortality and recovery in their analysis (14, 15, 22, 26) . Five RCT had high risk of bias due to missing outcome data (18-20, 22, 26). Four cohorts had serious risk of bias: Two studies were at serious risk of bias due to classification of interventions (16, 23) , and two studies had critical risk of bias due to confounding (14, 17) . In this analysis with four pre-print retrospective studies, and high risk of bias, ivermectin is not associated with reduced mortality (logRR 0.89, 95% CI 0.09 to 1.70, p = 0.04, I 2 = 84.7%, Figure 2a ). Additionally, ivermectin was not associated with reduced patient recovery (logRR 5.52 , 95% CI -24.36 to 35.4, p = 0.51, I 2 = 92.6%, Figure 2b ). No differences were found between the overall analysis and that proposed in the sensitivity analysis in terms of outcomes. For certainty of evidence and evaluation of study quality, the GRADE recommendation was used. Two outcomes were assessed: Mortality (3607 participants, 5 retrospective studies), and recovery (397 participants, 3 pre-print retrospective studies). Both showed a very low certainty of the evidence, based on study design, risk of bias, inconsistency, indirectness and imprecision ( Table 2) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.26.21250420 doi: medRxiv preprint We did not find a significantly reduction in the mortality and recovery of patients in the analyzed studies. It should be noted that the included studies are pre-print, so the information may vary and change the overall effect in our meta-analysis (although this trend may still be not significant). Ivermectin has been widely used on the basis of having an antiviral effect against SARS-Cov-2 (27). In this regard, a study published in Australia showed in-vitro effectiveness of ivermectin in Vero-cells; however, its clinical application in humans is very doubtful (5). This study was rapidly adopted by clinical practice guidelines, recommending ivermectin for the treatment of patients hospitalized with COVID-19, especially in countries severely affected by the pandemic. For example, Peru, one of the countries hardest hit by the pandemic, included Ivermectin as a first-line treatment, even as prophylaxis (28). The rationale to include this drug was based on its pharmacologic properties and application in other scenarios. Ivermectin belongs to the chemical group of avermectins, and is widely used in large animals for the treatment and control of parasitic infections, and to assist on the treatment of scabies and ticks. In humans, ivermectin has been used as a prophylactic drug in filariasis and as a therapeutic agent for scabies. It is a drug approved by the FDA and has shown to be safe in the recommended dosages (200 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. mortality was reduced in 2 out of the 3 included studies (OR 0.53, 95% CI 0.29-0.96). However, all these studies had a high risk of bias. One of the limitations of the study conducted by Padhy et al. is that the overall effect of ivermectin on mortality was analyzed without considering the reported effect measure . Furthermore, the analysis was performed without transforming the individual effect (from OR to LogOR, for example), thus the OR reported was overestimated. In another systematic review with networked meta-analysis, the effects of ivermectin on mortality were analyzed, and only two studies were included. The authors reported a very close statistical significance in terms of association of ivermectin with lower mortality (OR 0.15, 95% CI 0.04 to 0.57, p = 0.005); however, they pointed out that these data had very low certainty of evidence (31). Despite the small amount of highly biased evidence that has been published supporting the It is important to know that testing the efficacy of ivermectin in human clinical trials or observational study requires a previous evaluation in a dose-response trial, applying low dose (with less likelihood of pharmacological effect) and high dose relative to placebo. Given the lack of this type of studies, the ideal high dose of ivermectin has not been determined yet. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. ; Our study has some limitations that are worthy to mention. First, regarding heterogeneity, we found that five out of the eight studies were done in inpatients, two studies focused on outpatients only, and one study focused on both outpatients and inpatients. Similarly, we have found differences between treatment arms, for example, five studies reported the use of ivermectin by itself compared to the standard of care, and the remaining studies used ivermectin in combination with other drugs (dexamethasone, hydroxychloroquine, azithromycin). Although the outcome in hospitalized patients was overall mortality or recovery time, in outpatients the outcome was appearance of symptoms of Covid-19, except in one study (Carvallo) that measured disease severity and mortality. As observed, there is clinical heterogeneity that makes it difficult to combine the estimates in a pooled estimate. It is possible that the methodological heterogeneity and biases found in this systematic review and meta-analysis provided results inconsistent with reality. For this reason, it was proposed to meta-analyze the outcomes separately, assuming for each of them the model of random effects, and thus having greater precision in the effect. In spite of having statistical heterogeneity, the analysis of biases performed on the selected studies and the measurement of the size of the effect according to the outcome made a very close approximation to the reality. Finally, the LogRR and confidence intervals for mortality and recovery were found to be nonsignificant, and by applying GRADE, we determined the certainty of the evidence for this estimated effect: The true effect is likely to be substantially different from the estimated effect. This systematic review and meta-analysis concludes that more randomized clinical trials need to be included in a meta-analysis, with fewer biases to approximate more to the real measurable effect. At the moment, there is no evidence that the use of ivermectin changes the clinical outcome of inpatients or outpatients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. ; Khan . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. ; 6 9 / 7 1 . R D - 3 % ( - 6 % t o 1 % ) L o w . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Confidence interval; RR: Risk ratio GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 27, 2021. The Battle against COVID 19 Pandemic: What we Need to Know Before we Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Ivermectin: Potential Role as Repurposed Drug for COVID Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions RoB 2: a revised tool for assessing risk of bias in randomised trials GRADE handbook for grading quality of evidence and strength of recommendations Measuring inconsistency in metaanalyses Including non-randomized studies on intervention effects A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)